Frequently Asked Questions in the Management of SCCHN
Release date 23-10-2020
Expiration date 23-10-2021
The management of locally advanced (LA) and recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is highly complex, and physicians treating these patients often face clinical situations where treatment decision-making is challenging. View expert faculty presentations and downloadable slides from the recent SCCHN live webinar, Frequently Asked Questions in the Management of SCCHN, which includes discussion of some challenging clinical questions and guidance on the most appropriate treatment strategies.
Ye Guo, MD | Chair & Moderator
Department of Medical Oncology
Shanghai East Hospital Tongji
University School of Medicine
Ye Guo, MD, is the Deputy Director of the Oncology Department at Tongji University East Hospital in Shanghai, China. His research focuses on new drug development, and he serves as Director of the Phase I Trial Unit at Tongji University, Shanghai East Hospital. Previously, Dr. Guo led the research team for head and neck (H&N) cancer and lymphoma at Fudan University Shanghai Cancer Center where he has been Deputy Director of the Medical Oncology Department since 2010. He is the Deputy Secretary-General of the Chinese Society of Clinical Oncology (CSCO), Chairman of the H&N Cancer Committee (CSCO), member of the Standing Committee of the Union of Chinese Lymphoma Investigators (UCLI), Vice Chairman of the H&N Cancer Committee and Secretary-General of the Lymphoma Committee of Shanghai Anti-Cancer Association. Dr. Guo is a principal investigator for multiple key clinical trials of H&N cancer in China, and has published numerous articles in international, peer-reviewed journals.
Sandro Porceddu, MD, FRANZCR
Department of Radiation Oncology
Princess Alexandra Hospital
Faculty of Medicine, University of Queensland
Woolloongabba, Queensland, Australia
Professor Sandro Porceddu is a leading international head and neck (H&N) radiation oncologist and the current Director of Radiation Oncology Research at Princess Alexandra Hospital, and Professor of Medicine at the University of Queensland, Brisbane, Australia. He is Chair of the Cancer Alliance Queensland H&N Committee, Deputy Chair of the H&N International Group and serves on the Executive Committee of the International Federation of H&N Oncologic Societies (IFHNOS) and the Union for International Cancer Control (UICC) TNM International Expert Panel for H&N and Skin Cancer. Professor Porceddu runs an active clinical and translational research program involving Phase I, II and III trials in H&N and skin cancer. He has published over 150 clinical research articles, and is regularly invited to speak at prestigious cancer conferences. He was awarded a Doctorate of Medicine for his research on improving the integration of radiation therapy in the management of H&N cancer.
Jin Ching Lin, MD, PhD
Department of Radiation Oncology
Changhua Christian Hospital
Professor Jin-Ching Lin, MD, PhD is radiation oncologist at Changhua Christian Hospital and a part-time consultant at Taichung Veterans General Hospital, Taiwan where he served as a Director of Radiation Oncology (2004-2019). He has been a full professor at the National Yang-Ming University since 2007. Professor Lin won the outstanding research award from the National Science Council, Taiwan in 2004. He was leader of the educational training program for the Taiwan Society of Therapeutic Radiation Oncology (2008-2014) and Program Co-Director or Director of the Medical Engineering Division, Ministry of Science and Technology (2015- 2019). In 2018, Professor Lin was invited to be a member of the National Cancer Institute Head and Neck (H&N) Steering Committee on Clinical Trial Planning for Nasopharyngeal Cancer (NPC) in Bethesda, USA, and in 2020 he was invited to be a panel member for the CSCO-ASCO NPC Guidelines. His research interests focus on non-surgical treatments for all H&N cancers. Prof. Lin is internationally recognized as one of the pioneers in the field of circulating EBV DNA and NPC. He has published many articles in well recognized high impact journals.
- Key milestones in the management of SCCHN | Ye Guo, MD, PhD
- Frequently Asked Questions (FAQs)
- Q1. What treatment approach should I select for a cisplatin ‘’unfit’’ patient with LA SCCHN? | Sandro Porceddu, MD, FRANZCR
- Q2. How to treat a patient with LA SCCHN with local progression only? | Sandro Porceddu, MD, FRANZCR
- Q3. When is it appropriate to use induction chemotherapy (ICT) in LA SCCHN? | Jin Ching Lin, MD, PhD
- Q4. What sequencing strategies should I consider in a patient with R/M SCCHN? | Jin Ching Lin, MD, PhD
- Q5. How to recognize and manage hyperprogression during immunotherapy in R/M SCCHN? | Ye Guo, MD, PhD
This educational activity is designed for medical oncologists, radiation oncologists, otolaryngologists, and other healthcare professionals involved or interested in the management of patients with head and neck cancer.
Upon completion of this educational activity, participants should be able to:
- Define treatment options for patients with locally advanced (LA) SCCHN, including patients unfit for platinum-based therapy
- Select the optimal treatment approach for patients with recurrent/metastatic (R/M) SCCHN considering patient and disease characteristics and treatment availability
- Explain how to recognize and manage hyperprogression after immunotherapy in R/M SCCHN
Provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This on-demand webcast includes content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve knowledge, competence, and performance of clinicians in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Ye Guo has served as an advisor or consultant for Merck Serono, Boehringer Ingelheim, BMS, and MSD. He has served as a speaker or a member of a speakers bureau for Merck Serono, Roche, Celgene, Janssen, Bayer, BMS, and MSD. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Sandro Porceddu has served as an advisor or consultant for Merck Sharp & Dohme and Regeneron. He has served as a speaker or a member of a speakers bureau for Merck and Regeneron. Prof Porceddu has received grants for clinical research from Princess Alexandra Research Foundation. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Jin Ching Lin has no financial relationships to disclose. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.